Efficacy and Safety of Different Doses of Tirofiban on Serum Osteopontin and Periostin Content in STEMI Patients

The objective was to investigate the efficacy and safety of different doses of tirofiban in patients with acute ST-segment elevation myocardial infarction (STEMI) before percutaneous coronary intervention (PCI), and its effects on serum osteopontin and periostin and postoperative prognosis. A total of 210 patients with acute STEMI were divided into the control group, intravenous infusion of tirofiban (C-D group) and intravenous infusion 20 mu g/kg of loading dose of tirofiban (H-D group). The thrombolysis in myocardial infarction (TIMI) blood flow grades of the culprit vessel and cardiac function were observed. Serum levels of CRP, osteopontin and periostin were measured prior to PCI, and at 24 h and 30 days after PCI. The incidence of major adverse cardiac events (MACE) was followed up. Serum levels of CRP, osteopontin and periostin in C-D group and H-D group were significantly lower than of control group, and H-D group was significantly lower than C-D group. Postoperative TIMI flow grades of culprit vessel of H-D group and C-D group were obviously superior to that of control group, and postoperative TIMI in H-D group was superior to C-D group. Postoperative cardiac function showed that LVEF and NT-pro-BNP were significantly improved in H-D group and C-D group compared with control group during the hospitalization period, and the improvement of LVEF and NT-pro-BNP in H-D group was superior to C-D group. Follow-up for 6 months, the incidence of MACE events in control group was significantly higher than that of C-D group and H-D group. In conclusion, application of triofiban in early stage of STEMI patients can attenuate the increase of serum levels of CRP, osteopontin and periostin and reducing the incidence of MACE at 6 months after surgery.